Already a member? Sign in
Natalizumab is a monoclonal antibody given by infusion and used in the treatment of MS and Crohn's disease. It has been shown to slow progression and reduce relapses in MS. It is currently sold under the brand name Tysabri.
| Purpose | # of patients |
# of patients with evaluations
Efficacy
|
Major | Moderate | Slight | None | Can’t tell |
|---|---|---|---|---|---|---|---|
| MS (Multiple Sclerosis) | 1399 | 497 |
|
|
|
|
|
| Other | 34 | 9 |
|
|
|
|
|
| Improve mobility | 26 | 12 |
|
|
|
|
|
| General health | 23 | 6 |
|
|
|
|
|
| Fatigue | 22 | 11 |
|
|
|
|
|
| Stiffness/Spasticity | 20 | 8 |
|
|
|
|
See all 1357 patients currently taking Natalizumab
Mouse over the table for more information
Commonly reported side effects, conditions, and hospitalizations associated with Natalizumab
| Headaches | 60 | |
|---|---|---|
| Tiredness | 53 | |
| Fear of PML | 25 | |
| Fatigue | 17 | |
| Stomach pain | 14 | |
| Urinary Tract Infection UTI | 14 | |
| See all 183 reported side effects ▼ | ||
Frequently reported dosages based on patients currently taking Natalizumab. See all 28 dosages ►
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Doctor's advice | 129 | ||
| Side effects too severe | 125 | ||
| Other | 117 | ||
| Did not seem to work | 93 | ||
| Personal research | 31 | ||
| Expense | 21 | ||
| Course of treatment ended | 11 | ||
| Change in health plan coverage | 9 | ||
| Not indicated | 4 |
Adherence
Taking treatment as prescribed
Adherence of Natalizumab
Always |
493 | 93% |
|
|---|---|---|---|
Usually |
25 | 5% |
|
Sometimes |
2 | 0% |
|
Never |
12 | 2% |
|
Burden
Difficulty being on treatment
Burden of Natalizumab
Very |
27 | 5% |
|
|---|---|---|---|
Somewhat |
70 | 13% |
|
A little |
141 | 27% |
|
Not at all |
294 | 55% |
|
Cost
Paid out of pocket
Cost of Natalizumab
$200+ |
89 | 24% |
|
|---|---|---|---|
$100-199 |
25 | 7% |
|
$50-99 |
33 | 9% |
|
$25-49 |
34 | 9% |
|
< $25 |
183 | 49% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on February 12, 2012.